Abstract
Purpose :
To report the results of our clinical survey on subcutaneous triamcinolone acetonide eyelid (STAE) injection for vernal keratoconjunctivitis (VKC).
Methods :
Fifteen VKC patients were recruited for the clinical survey on STAE injections in Fukuoka University Hospital. All had past histories of single or multiple STAE injections. It was a closed question survey with yes or no answers. Survey was responded by either the patients themselves or by the guardian when the patient had not reached a reading age. Survey included questions on how the patient felt during the STAE injection, how symptoms have changed after the injection, any symptoms of side effects, and if the patient would want another STAE injection when symptoms recurred.
Results :
Average age of initial STAE injection was 11.4 years old (5-24 years old). Fourteen male and one female were included. Average repeated injections were 4.1 times(1-10 times). Ten out of 15 were frightened during the injection, 14 out of 15 felt immediate relief in eye symptoms, 9 out of 15 had no signs of any side effects, and 11 out of 15 would do repetitive STAE injections when symptoms recurred. Average age of initial injection of three cases denied STAE injections was 7.33 years old, and this group was significantly younger than the group which wants to receive STAE injections (t test, p=0.023).
Conclusions :
Our clinical survey provided insights into the changing of adjunctive VKC treatment with STAE injection. Survey revealed an immediate relief of symptoms after the injection and despite of being frightened during the procedure, most of the patients were willing to go through the procedure again when symptoms recurred.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.